Exosomes in Cancer Diagnosis and Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 91491
Special Issue Editor
Interests: cancer metastasis; cancer drug resistance; epigenetics; non-coding RNAs; miRNAs; breast cancer; prostate cancer; lung cancer; meningioma; pancreatic cancer; cancer health disparity
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Exosomes are the smallest type of extracellular vesicles that play a role in the communications between cells. They act as cargo-carriers, with their cargo consisting of many molecules derived from the cells that they originate from. Among other molecules, proteins, RNA, microRNAs, non-coding RNAs etc. have generated particular interest among the researchers as their exosome-mediated transfer to recipient cells is believed to confer many survival advantages. Exosomes can influence immune responses and the processes as diverse as angiogenesis, metastasis, drug resistance and metastasis. Thus, their potential exploitation as therapeutic targets has been advocated. At the same time, exosomes have been detected in various biological fluids, such as, blood, urine and cerebrospinal fluids, thus, pointing to their use in the diagnosis of human cancers. This special issue covers all the topics relevant to the validation and/or targeting of exosomes in human cancers.
Dr. Aamir Ahmad
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- exosomes
- CD9
- CD81
- cancer
- diagnostic biomarkers
- dancer therapy
- angiogenesis
- drug resistance
- metastasis
- mRNA
- miRNA
- non-coding RNAs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.